organization · Reporting owner
Decheng Capital China Life Sciences USD Fund II, L.P.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BeyondSpring Inc.
Report date October 16, 2025 · Filed October 21, 2025
Jointly reported with Decheng Capital China Life Sciences USD Fund III, L.P., Decheng Capital Management III (Cayman), LLC, Decheng Capital Management II (Cayman), LLC, Decheng Capital Global Healthcare Fund (Master), LP, Decheng Capital Global Healthcare GP, LLC, Cui Xiangmin
Section 16 reporting ended · disclosed 2025-10-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Decheng Capital China Life Sciences USD Fund III, L.P. | 1,518,893 |
Last balance in matching sequence
After 2025-10-17 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2025-10-16 · Sale · Disposed 85,798 · Balance 1,564,406 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.62 to $1.795 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Row 2 · 2025-10-17 · Sale · Disposed 45,513 · Balance 1,518,893 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.73 to $1.80 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Decheng Capital China Life Sciences USD Fund II, L.P. | 1,617,409 |
Reported balance
Holding disclosure · report date 2025-10-16 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,617,409 F4: These securities are held directly by Decheng Capital China Life Sciences USD Fund II, L.P. ("Fund II"). Decheng Capital Management II (Cayman), LLC ("GP II") is the general partner of Fund II. Dr. Cui is the manager of GP II. Each of Fund II, GP II and Dr. Cui may be deemed to beneficially own the securities held by Fund II. Each of GP II and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Decheng Capital Global Healthcare Fund (Master), LP | 891,734 |
Reported balance
Holding disclosure · report date 2025-10-16 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 891,734 F5: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.62 to $1.795 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.73 to $1.80 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: These securities are held directly by Decheng Capital China Life Sciences USD Fund II, L.P. ("Fund II"). Decheng Capital Management II (Cayman), LLC ("GP II") is the general partner of Fund II. Dr. Cui is the manager of GP II. Each of Fund II, GP II and Dr. Cui may be deemed to beneficially own the securities held by Fund II. Each of GP II and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.
F5: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2025 Filed Aug 11, 2025 21:07 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 2,152 | $2.28 | $4,906.56 |
DisclosureSEC source: 0001415889-25-021441 · form4-08112025_090812.xml · nonDerivative · entry 13 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital Global Healthcare Fund (Master), LP Disclosed balance after: 920,798 F1 · ownership.nature: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| July 14, 2025 Filed Aug 11, 2025 21:07 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 801 | $2.29 | $1,834.29 |
DisclosureSEC source: 0001415889-25-021441 · form4-08112025_090812.xml · nonDerivative · entry 12 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital Global Healthcare Fund (Master), LP Disclosed balance after: 922,950 F1 · ownership.nature: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| July 11, 2025 Filed Aug 11, 2025 21:07 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 246 | $2.29 | $563.34 |
DisclosureSEC source: 0001415889-25-021441 · form4-08112025_090812.xml · nonDerivative · entry 11 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital Global Healthcare Fund (Master), LP Disclosed balance after: 923,751 F1 · ownership.nature: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| July 10, 2025 Filed Aug 11, 2025 21:07 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 768 | $2.28 | $1,751.04 |
DisclosureSEC source: 0001415889-25-021441 · form4-08112025_090812.xml · nonDerivative · entry 10 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital Global Healthcare Fund (Master), LP Disclosed balance after: 923,997 F1 · ownership.nature: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| July 09, 2025 Filed Aug 11, 2025 21:07 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 252 | $2.27 | $572.04 |
DisclosureSEC source: 0001415889-25-021441 · form4-08112025_090812.xml · nonDerivative · entry 9 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital Global Healthcare Fund (Master), LP Disclosed balance after: 924,765 F1 · ownership.nature: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| July 08, 2025 Filed Aug 11, 2025 21:07 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 9,059 | $2.29 | $20,745.11 |
DisclosureSEC source: 0001415889-25-021441 · form4-08112025_090812.xml · nonDerivative · entry 8 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital Global Healthcare Fund (Master), LP Disclosed balance after: 925,017 F1 · ownership.nature: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| July 02, 2025 Filed Aug 11, 2025 21:07 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 324 | $2.42 | $784.08 |
DisclosureSEC source: 0001415889-25-021441 · form4-08112025_090812.xml · nonDerivative · entry 7 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital Global Healthcare Fund (Master), LP Disclosed balance after: 934,076 F1 · ownership.nature: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| July 01, 2025 Filed Aug 11, 2025 21:07 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 600 | $2.43 | $1,458.00 |
DisclosureSEC source: 0001415889-25-021441 · form4-08112025_090812.xml · nonDerivative · entry 6 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital Global Healthcare Fund (Master), LP Disclosed balance after: 934,400 F1 · ownership.nature: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| June 23, 2025 Filed Aug 11, 2025 21:07 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 1,700 | $3.09 | $5,253.00 |
DisclosureSEC source: 0001415889-25-021441 · form4-08112025_090812.xml · nonDerivative · entry 5 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund II, L.P. Disclosed balance after: 1,617,409 F5 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $3.06 to $3.19 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund II, L.P. ("Fund II"). Decheng Capital Management II (Cayman), LLC ("GP II") is the general partner of Fund II. Dr. Cui is the manager of GP II. Each of Fund II, GP II and Dr. Cui may be deemed to beneficially own the securities held by Fund II. Each of GP II and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| June 20, 2025 Filed Aug 11, 2025 21:07 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 225,217 | $3.16 | $711,685.72 |
DisclosureSEC source: 0001415889-25-021441 · form4-08112025_090812.xml · nonDerivative · entry 4 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund II, L.P. Disclosed balance after: 1,619,109 F4 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $3.05 to $3.27 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund II, L.P. ("Fund II"). Decheng Capital Management II (Cayman), LLC ("GP II") is the general partner of Fund II. Dr. Cui is the manager of GP II. Each of Fund II, GP II and Dr. Cui may be deemed to beneficially own the securities held by Fund II. Each of GP II and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| June 20, 2025 Filed Aug 11, 2025 21:07 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 60,000 | $3.11 | $186,600.00 |
DisclosureSEC source: 0001415889-25-021441 · form4-08112025_090812.xml · nonDerivative · entry 3 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital Global Healthcare Fund (Master), LP Disclosed balance after: 935,000 F1 · ownership.nature: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| June 18, 2025 Filed Aug 11, 2025 21:07 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 59,253 | $3.17 | $187,832.01 |
DisclosureSEC source: 0001415889-25-021441 · form4-08112025_090812.xml · nonDerivative · entry 2 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund II, L.P. Disclosed balance after: 1,844,326 F2 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $3.10 to $3.34 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund II, L.P. ("Fund II"). Decheng Capital Management II (Cayman), LLC ("GP II") is the general partner of Fund II. Dr. Cui is the manager of GP II. Each of Fund II, GP II and Dr. Cui may be deemed to beneficially own the securities held by Fund II. Each of GP II and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| June 17, 2025 Filed Aug 11, 2025 21:07 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 5,000 | $3.23 | $16,150.00 |
DisclosureSEC source: 0001415889-25-021441 · form4-08112025_090812.xml · nonDerivative · entry 1 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital Global Healthcare Fund (Master), LP Disclosed balance after: 995,000 F1 · ownership.nature: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.